SCHEMBL1097407

SCHEMBL1097407

CN(C)CCN(c1sc2ccccc2c1Br)S(=O)(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.37
NFE2L2 Q16236 3/20 0.37
TRPM8 Q7Z2W7 4/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
SLC6A4 P31645 1/20 0.36
HSD11B1 P28845 1/20 0.36
HTR6 P50406 3/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR1F P30939 1/20 0.35
HTR7 P34969 1/20 0.35
DRD3 P35462 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTGS2 P35354 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ATM Q13315 1/20 0.34
C1R P00736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098422 0.90 TRPM8 (0.49) KEAP1NFE2L2TRPM8
SCHEMBL1098503 0.86 TDP1 (0.49) KEAP1NFE2L2TRPM8TDP1ATM
SCHEMBL1099122 0.86 TRPM8 (0.37) KEAP1NFE2L2TRPM8HSD11B1TDP1
SCHEMBL1098799 0.86 C1R (0.44) KEAP1NFE2L2TRPM8HSD11B1C1R
SCHEMBL1099972 0.85 TRPM8 (0.37) KEAP1NFE2L2TRPM8HSD11B1TDP1
SCHEMBL1099417 0.85 NR1I2 (0.47) KEAP1NFE2L2TRPM8HSD11B1PTGS2
SCHEMBL1098844 0.85 NR1I2 (0.44) KEAP1NFE2L2TRPM8PTGS2KDM4E
SCHEMBL1099333 0.85 ALDH1A1 (0.42) KEAP1NFE2L2TRPM8HTR2AHTR2C
SCHEMBL1098270 0.84 ALOX5 (0.44) KEAP1NFE2L2TRPM8HTR2AHTR6
SCHEMBL1099577 0.84 RORC (0.48) KEAP1NFE2L2TRPM8HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 CN disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885TRPM8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.